Meet the Inventor of SmartVascular Dx
Dr. Douglas Harrington
“The SmartVascular DX test will identify the beginnings of the inflammatory process that will lead to more severe disease.”
Douglas Harrington M.D.
Dr. Harrington is the inventor of the Smart Vascular Dx test, a breakthrough blood test for the detection of vascular inflammation, the leading cause of heart attacks, metabolic syndromes, autoimmune diseases and cancer. He is currently Chairman, Founder, Chief Medical Officer and Chief Science Officer of Smart Health Diagnostics Company. Dr. Harrington was a Clinical Professor of Pathology at the USC Keck School of Medicine for 15 years and prior to that an Associate Professor at the University of Nebraska Medical Center.
He is a published author of numerous peer-reviewed papers, and a sought-after speaker in the area of preventive medicine and technology development. Dr. Harrington received his BA in molecular biology, his MD from the University of Colorado Health Sciences Center, and is a Fellow of the American Society of Preventive Cardiology and member of the European Society of Cardiology. He is also board-certified in hematology, and anatomic and clinical pathology.
Dr. Harrington has over 35 years of experience in the research, development, and translation of academic healthcare discovery into clinical use. He was a resident member of one of the first heart transplant teams led by Dr. Jack Copeland from Stanford University.
Dr. Harrington co-founded one of the first clinical molecular biology laboratories with the Nebraska Lymphoma Study Group headed by Dr. Jim Armitage.
As President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings.
He led the team that developed one of the first FDA approved digital microscopes targeted at minimal residual disease and circulating tumor cells as the founder and CEO of Clarient. Dr. Harrington also led the turnaround and reinstatement of the Federal license of Specialty Laboratories, a New York Stock Exchange company, as CEO and Laboratory Director.
Dr. Harrington has patents for an automated method for image analysis of residual cancer cells, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies - from devices to molecular genetics focusing on immunology, cancer and cardiology. He has taken a number of new molecular technologies through state and federal regulatory approval and has been involved in the commercialization of over 200 academic discoveries. He is a member of Phi Beta Kappa, the nation’s most prestigious academic honor society.